FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1559-1561 November 20, 1997 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Moreland, L. W. PubMed Citation

To the Editor: Moreland et al. (July 17 issue)¹ report that the administration of a recombinant human tumor necrosis factor receptor (p75)–Fc fusion protein (TNFR:Fc) to adults with refractory rheumatoid arthritis results in significantly more improvement in the inflammatory symptoms than placebo injections. This conclusion is highly dependent on the blinding of the clinical trial. The results of open and double-blind trials of anti-CD4 therapy make clear that the outcome variables used by Moreland et al.¹ are highly susceptible to expectation bias.² Although the design of the study included initial blinding, the question is whether such blinding was maintained for . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.